Introduction
============

Lung cancer as a major non-communicable disease pertains to one of the most common cancers with the highest incidence and mortality rates in all human malignant tumors.[@b1-ott-11-4197],[@b2-ott-11-4197] Generally, the occurrence, development, metastasis, and drug resistance of tumors are closely related to tumor microenvironment.[@b3-ott-11-4197] Commonly accepted, radiotherapy, chemotherapy, traditional Chinese medicine, and their conjunctions are the approaches for lung cancer treatment.[@b4-ott-11-4197]--[@b7-ott-11-4197] Despite significant advances made in research into the progression, development, and prognosis of lung cancer over the past few decades, the outcome of most patients afflicted with lung cancer has not remarkably improved. Recently, researchers have disclosed that the vast majorities of human genome are indeed transcribed into various types of non-coding RNAs (ncRNAs) without protein-coding ability, including small ncRNAs (RNA transcript length \<200 nt) and long ncRNAs (lncRNAs, RNA transcript length \>200 nt).[@b8-ott-11-4197] Increasing studies have manifested that lncRNAs are widely implicated in a variety of human cancers, including lung cancer,[@b9-ott-11-4197] colorectal cancer,[@b10-ott-11-4197] esophageal cancer,[@b11-ott-11-4197] gastric cancer,[@b12-ott-11-4197] and osteosarcoma.[@b13-ott-11-4197] Certainly, numerous lncRNAs have also been found to be related with the occurrence and development of lung cancer. For example, SNHG7 has been reported as an oncogene evidenced by increasing the proliferative, migrative, and invasive abilities, as well as reducing apoptotic potential of lung cancer cells by elevating the expression levels of FAIM2 associated with obesity.[@b14-ott-11-4197] PCAT6[@b15-ott-11-4197] and CPS1-IT1[@b16-ott-11-4197] were also identified to suppress cell proliferation as an anti-oncogene in human lung cancer. Long intergenetic non-coding RNAs (lincRNAs), belonging to lncRNAs, have been uncovered in the poor-studied genomic regions with many alluring properties, such as associations with various human diseases, tissue-specific expression, and expression changes during development.[@b17-ott-11-4197]--[@b19-ott-11-4197]

As previously reported, lincRNA TCONS_00029157, termed SIK1-LNC in our paper, showed a positive tendency with SIK1 in multiple cancers.[@b20-ott-11-4197] In our previous work, we found that SIK1-LNC is located at chromosome 21q22.3, ranging from 43,358,055--43,362,688 bp and adjacent to salt-inducible kinases 1 (SIK1) based on the data from the University of California Santa Cruz (UCSC) website.[@b36-ott-11-4197] Commonly, mounting evidence has revealed that lncRNA can exert its function by targeting either neighboring genes of the same chromosome (in cis) or distantly located genes of the same or different chromosome (in trans).[@b21-ott-11-4197],[@b22-ott-11-4197] SIK1, a serine/threonine kinase, belongs to the stress- and energy-sensing AMPK family of kinases, all of which play vital roles in regulation of metabolism and cell growth.[@b23-ott-11-4197] Recently, emerging evidence has elucidated that SIK1 performs a crucial role in certain human cancers, such as gastric adenocarcinoma[@b24-ott-11-4197] or epithelial ovarian cancer.[@b25-ott-11-4197] Particularly in non-small-cell lung cancer, it has been demonstrated that attenuated LKB1-SIK1 signaling enhances epithelial mesenchymal transition and radioresistance of non-small-cell lung cancer cells, which subsequently contributes to the enhanced metastatic potential.[@b9-ott-11-4197] We, thus, deduced that SIK1 might be a contributor to treatment failure and poor prognosis in non-small-cell lung cancer. In fact, it has been reported that reduced levels of SIK1 are closely correlated with poor outcome in diverse cancers,[@b24-ott-11-4197] and SIK1 coupled with LKB1 can suppress tumor metastasis.[@b26-ott-11-4197] However, the expression profile and functional role of SIK1-LNC in lung cancer cells remains largely unclear, which calls for further investigation.

In this study, we first investigated the expression pattern of SIK1-LNC and SIK1 in lung cancer tissues and presented the correlation of SIK1-LNC expression and clinicopathologic features. The association of SIK1-LNC and SIK1 expression in lung cancer cells was also explored. The potentially functional roles of SIK1-LNC in the viability, proliferation, migration, and invasion of lung cancer cells were finally analyzed. The data would provide the theoretical basis for the clinic research of lung cancer in the near future.

Materials and methods
=====================

Patient samples
---------------

The utilization of samples for this study was approved by the ethical committee of Zhongnan Hospital of Wuhan University. Thirty patients with non-small-cell lung carcinoma who received surgical resection from 2013 to 2014 in Zhongnan Hospital of Wuhan University were selected for this study. All clinical characteristics of patients are listed in [Table 1](#t1-ott-11-4197){ref-type="table"}. Of the 30 patients, no one underwent preoperative therapy such as radiotherapy or chemotherapy prior to initial surgery. Also, everyone has signed written informed consent before tumor sample collection. Tissue samples collected at surgery were immediately snap-frozen by liquid nitrogen and stored at −80°C for RNA extraction.

Cancer cell lines
-----------------

Human lung cancer epithelial cell lines (namely BEAS-2B, A549, H1975, and H460) were acquired from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). All of them were maintained in RPMI-1640 medium (Gibco BRL, Grand Island, NY, USA) at 37°C in a humidified 5% (v/v) CO~2~ atmosphere. Ten percent fetal bovine serum, 100 U/mL of penicillin and 100 µg/mL of streptomycin were added into RPMI-1640 medium. Exponentially growing cells were selected for all the experiments in this work.

Quantitative real-time polymerase chain reaction (RT-qPCR) analysis
-------------------------------------------------------------------

In accordance with the manufacturer's protocol, total RNA was extracted from 30 lung cancer tissues and matched adjacent normal tissues using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). RNA was reversely transcribed into complementary DNA using PrimeScript™ One Step RT-PCR kit (Takara Biotechnology Co., Ltd., Dalian, China), and RT-qPCR was performed using the SYBR PrimeScript RT-PCR kit (Takara, Ohstu, Japan) on an Applied Biosystems 7500 Fluorescent Quantitative PCR System (Applied Biosystems, Foster City, CA, USA). The primers were designed and synthesized by GenePharma (Shanghai, China), and all sequences we used are depicted in [Table 2](#t2-ott-11-4197){ref-type="table"}. The reaction conditions were designed as follows: an initial single cycle of 30 seconds at 95°C, followed by 40 cycles of 5 seconds at 95°C and finally 34 seconds at 60°C. GAPDH was used as the normal control in this work. The ΔΔCT calculation with CT served as the threshold cycle for quantification of gene expression, and the target gene expression level in the patient was measured as the ratio (target in tumor tissue/target in non-tumorous tissue: R \[T/N\]).

Western blot analysis
---------------------

Cells were rinsed with ice-cold PBS harvested and lysated in the lysis buffer (40 nM Tris \[pH 7.4\], 150 mM NaCl, 10 mM ethylene diamine tetraccetic acid, 10% glycerol, 1% Triton X-100, 10 mM glycerophosphate, 1 mM Na~3~VO~4~, and 1 mM phenylmethylsulfonyl fluoride) contained with protease inhibitor (Roche Applied Science, Indianapolis, IN, USA). Proteins were separated on a NuPAGE 4%--12% Bis-Tris Gel (Invitrogen) and then transferred onto a polyvinylidene difluoride membrane (Invitrogen). The membrane was blocked for 60 minutes with 5% skim milk at room temperature, incubated with the primary antibody overnight at 4°C followed by incubation with corresponding secondary antibody. Finally, the membrane was developed by enhancing chemiluminescence solutions (Thermo Fisher Scientific) and detected using the Mini Chemiluminescent Imaging and Analysis System (Sage, China).

Overexpression of SIK1-LNCin lung cancer cells
----------------------------------------------

The SIK1-LNC low-expressed A549 cells were selected to perform the overexpression experiments. The pcDNA SIK1-LNC was constructed by introducing a BamHI-EcoRI fragment into the homologous site in pcDNA3.1, and the introduced BamHI-EcoRI fragment embodied SIK1-LNC cDNA. Following the manufacturer's instructions, pcDNA SIK1-LNC, and pcDNA control were respectively transfected into A549 cells using Lipofectamine 2000 (Invitrogen). After 48 hours of transfection, cells were applied for RNA isolation, cell proliferation, migration, and invasion assays.

Knockdown of SIK1-LNC and SIK1 in lung cancer cells
---------------------------------------------------

Knockdown experiments were carried out in SIK1-LNC high-expressed H460 cells. The small interfering RNAs (siRNAs) for target genes SIK1-LNC (SIK1-LNC si1 and SIK1-LNC si2), negative control siRNA (NC si), and SIK1 (SIK1 si1 and SIK1 si2) were acquired from GenePharma (Shanghai, China), and the sequences are listed in [Table 2](#t2-ott-11-4197){ref-type="table"}. Prior to transfection with siRNAs, 5% H460 cells were seeded into 12-well culture plates and maintained for at least 24 hours to achieve a confluence of 30%--50%. According to the manufacturer's recommendations, siRNA transfections were fulfilled with X-tremeGENE transfection reagent (Roche). Those transfected cells were harvested for RNA isolation, cell proliferation, migration, and invasion assays at 48 hours post-transfection.

Cell viability assays
---------------------

The viability of transfected cells was assessed by Cell Counting Kit-8 (CCK-8) according to the manufacturer's recommendation (Dojindo Molecular Technologies, Inc., Kumamoto, Japan). Cells transfected with pcDNA or siRNAs were both plated into 96-well plates containing 100 µL of culture medium. Afterwards, CCK-8 (10 µL/well) solution was added to measure cell viability at the designed intervals (0, 24, 48, and 72 hours of incubation). After 2 hours of further incubation at 37°C in 5% CO~2~, the absorbance of each well was measured at a wavelength of 450 nm by a Model 680 Microplate Reader (Bio-Rad, Richmond, CA, USA).

Cell proliferation assays
-------------------------

The proliferative capacity of the transfected cell was assessed using the bromodeoxyuridine (Brdu) incorporation assay kits (Millipore, Billerica, MA, USA). Briefly, cells (1×10[@b4-ott-11-4197]) were seeded in each well of a 96-well plate after 48 hours of transfection. 10 µL of Brdu was subsequently added to each well. After 5 hours incubation, cells were fixed by FixDenat for 30 minutes. Cells were then incubated with anti-Brdu antibody in incubation buffer from Roche for 1 hour at 37°C. Cell nuclei were stained with 1 µM SYTOX Green (S7020, Life Technologies) at room temperature for 15 minutes. In each treatment, cells were washed with PBS at least three times.

Scratch wound-healing assay
---------------------------

The scratch wound healing assay was employed to evaluate the migratory properties of lung cancer cells. Cells at the density of 5×10^5^ cells per well were seeded into plastic 12-well plates and cultured for 12 hours. Uniform wounds were scraped in monolayer cells using a 10 µL pipette tip after being transfected with pcDNA or siRNAs. Wound healing gaps in each group were measured under an optical microscope at 0 and 48 hours.

Cell invasion assays
--------------------

The invasive properties of transfected cells were examined using transwell chambers invasion assays (8 µm; Corning Incorporated, Corning, NY, USA). After 48 hours of transfection, cells were added into the upper chamber of transwells, and the lower chamber was filled up with complete growth medium. After incubating for 22 hours at 37°C, the non-invading cells were wiped off from the upper surface of membranes, while the invaded cells were stained with 0.5% crystal violet solution. The number of invaded cells pre-well was counted by a microscope ×200 magnification in random fields. All experiments were conducted at least three times.

Statistical analyses
--------------------

Each presented experiment was performed at least three times, and data were presented as means ± standard deviation (SD). SPSS version 18.0 software (SPSS Inc, Chicago, IL, USA) was used for all statistical analyses. A chi-squared test was employed to evaluate the correlation between SIK1-LNC expression and clinicopathologic features of lung cancer patients. Comparison of different groups was analyzed using the Student's *t*-test and a one-way analysis of variance. A value of *P*\<0.05 was considered statistically significant.

Results
=======

SIK1 and SIK1-LNC were remarkably down-regulated in lung cancer tissue samples
------------------------------------------------------------------------------

RT-qPCR was performed to detect SIK1 and SIK1-LNC expressions in 30 patient samples. The data suggested that both SIK1 and SIK1-LNC expressions were comparatively down-regulated when compared to those in matched adjacent normal tissues ([Figure 1A and B](#f1-ott-11-4197){ref-type="fig"}, *P*\<0.05). In addition, the correlation between SIK1-LNC expression and clinicopathologic features of lung cancer patients were also assessed. As shown in [Table 1](#t1-ott-11-4197){ref-type="table"} (*P*\<0.05), SIK1-LNC expression was significantly correlated with lymph node metastasis, distant metastasis. According to correlation analysis (n=30), we found that SIK1-LNC expression was closely associated with SIK1 expression ([Figure 1C](#f1-ott-11-4197){ref-type="fig"}, *P*\<0.05). By this token, we extrapolated that SIK1 expression may have a positive tendency with SIK1-LNC expression.

SIK1 expression showed a positive tendency with SIK1-LNC expression in lung cell lines
--------------------------------------------------------------------------------------

Using RT-qPCR, we examined the SIK1 and SIK1-LNC expressions in four lung cancer cell lines, namely BEAS-2B, A549, H1975, and H460. The results suggested that SIK1-LNC achieved the highest level in H460 and the lowest in A549. So was the case in SIK1 expression ([Figure 2A](#f2-ott-11-4197){ref-type="fig"}). Low-expressed A549 cells were, therefore, selected to conduct the overexpression experiment, while high-expressed H460 cells were prepared for the knockdown experiment. In SIK1 knockdown experiments, the expression levels of SIK1 were verified, and those of SIK1-LNC remained almost unchanged in cells transfected with either SIK1 si1 or SIK1 si2 when compared to the NC si group ([Figure 2B](#f2-ott-11-4197){ref-type="fig"}; *P*\<0.05). Next, overexpression and knockdown experiment of SIK1-LNC was conducted and analyzed by RT-qPCR and Western blot assays, respectively. In the SIK1-LNC over-expression experiment, pcDNA SIK1-LNC was constructed and transfected into A549 cells. RT-qPCR analysis suggested that SIK1 and SIK1-LNC expressions at mRNA level in the pcDNA SIK1-LNC group were prominently elevated in contrast with the pcDNA control group. A similar result was obtained in regard to the expression of SIK1 at protein level, as determined by Western blot assay ([Figure 2C](#f2-ott-11-4197){ref-type="fig"}; *P*\<0.05). Conversely, in the SIK1-LNC knockdown experiment, the expression of SIK1 at both mRNA and protein levels was evidently lower in cells transfected with either SIK1-LNC si1 or SIK1-LNC si2 when compared to the NC si group ([Figure 2D](#f2-ott-11-4197){ref-type="fig"}; *P*\<0.05). Conjointly, these findings indicated that the SIK1 expression presented a positive tendency with SIK1-LNC expression in lung cancer cells.

SIK1-LNC overexpression impaired cell viability, proliferative, migrative, and invasive abilities of A549 cells
---------------------------------------------------------------------------------------------------------------

Cell viability, proliferation, migration, and invasion assays were conducted to investigate the functional role of SIK1-LNC. The pcDNA SIK1-LNC and pcDNA control were constructed for the above experiments. The CCK-8 assay indicated that A549 cell viability in pcDNA SIK1-LNC groups was significantly lower than that in the pcDNA control group ([Figure 3A](#f3-ott-11-4197){ref-type="fig"}, *P*\<0.05). The Brdu assays showed that the cell proliferation properties were apparently impaired more than 40% in the pcDNA SIK1-LNC group when compared with the pcDNA control group ([Figure 3B](#f3-ott-11-4197){ref-type="fig"}, *P*\<0.05). Similarly, the wound healing and invasion assays, respectively, indicated that the pcDNA SIK1-LNC group showed significant inhibition on cell migration and invasion in contrast with the pcDNA control group. More concretely, the number of migrated cells in the pcDNA SIK1-LNC group nearly dropped to half as compared to the pcDNA control group and the number of invasive cells in the pcDNA SIK1-LNC group was over three times lower than those in the pcDNA control ([Figure 3C](#f3-ott-11-4197){ref-type="fig"} and D, *P*\<0.05). Taken together, our findings revealed that SIK1-LNC overexpression could impair cell viability, proliferative, migrative, and invasive abilities of A549 cells.

SIK1-LNC knockdown promoted cell viability, proliferative, migrative, and invasive abilities of H460 cells
----------------------------------------------------------------------------------------------------------

With the aim of investigation into the functional role of SIK1-LNC in lung cancer cells, knockdown experiments were conducted by transfecting H460 cells with SIK1-LNC si or NC si. It could be observed that the cell viabilities in SIK1-LNC si-transfected groups were gradually higher than those in the NC si group according to CCK-8 assays, and the cell viabilities in SIK1-LNC si-transfected groups had nearly doubled ([Figure 4A](#f4-ott-11-4197){ref-type="fig"}; *P*\<0.05). The Brdu assays revealed that the cell proliferation abilities of H460 cells were dramatically impaired in SIK1-LNC si-transfected groups when compared with those in the NC si group. Specifically, cell proliferation abilities in SIK1-LNC si-transfected groups were also increased by \~10% ([Figure 4B](#f4-ott-11-4197){ref-type="fig"}, *P*\<0.05). Likewise, the wound healing and invasion assays manifested a remarkable elevation of cell migration and invasion capacities both in SIK1-LNC si-transfected groups compared with the NC si group. Clearly, cell migration ability increased by \~40% in the SIK1-LNC si-transfected groups, and the cell invasion ability in SIK1-LNC si-transfected groups was over three times more than in the NC si group ([Figure 4C and D](#f4-ott-11-4197){ref-type="fig"}, *P*\<0.05). Consequently, these results demonstrated that SIK1-LNC knockdown could advance cell viability, prolif-erative, migrative, and invasive abilities of H460 cells.

Discussion
==========

Recently, mounting studies have demonstrated that lncRNAs are of great significance in cancerogenesis and cancer progression. LncRNAs have become a sharp focus in cancer diagnosis and treatment research.[@b27-ott-11-4197]--[@b29-ott-11-4197] It has been reported that aberrantly expressed lncRNAs might serve as biomarkers for the early diagnosis of various human cancers, such as lung cancer,[@b9-ott-11-4197],[@b14-ott-11-4197]--[@b16-ott-11-4197] hepatocellular carcinoma,[@b30-ott-11-4197] gastric cancer,[@b12-ott-11-4197],[@b31-ott-11-4197],[@b32-ott-11-4197] mesenchymal glioma,[@b33-ott-11-4197] and prostate cancer.[@b34-ott-11-4197],[@b35-ott-11-4197]

In this study, we found a novel tumor suppressor SIK1-LNC is adjacent to protein coding gene SIK1. Commonly, the expression and function of lncRNAs are associated with adjacent protein coding transcripts.[@b21-ott-11-4197],[@b22-ott-11-4197] Therein SIK1 has been reported to be positively linked with the treatment of lung cancer,[@b9-ott-11-4197] and recognized as a potential tumor suppressor in lung cancer. Accordingly, we speculated that SIK1-LNC may be involved in lung cancer development, and its obscure effect on lung cancer spurs us to conduct this research.

In this present study, we found that SIK1-LNC expression was in line with SIK1 expression. Therefore, we deduced that SIK1-LNC may also be implicated in multiple biological processes in lung cancer like cell viability, proliferation, migration, and invasion. To confirm our deduction, the functional experiments of SIK1-LNC in lung cancer cells were performed. We firstly disclosed that SIK1-LNC expression was down-regulated in lung cancer cells and bound up with clinicopathologic features including lymph node metastasis and distant metastasis. This conveyed the possibility of the regulatory role of SIK1-LNC in the occurrence and progression of lung cancer. Subsequently, cell viability, proliferation, migration, and invasion assays were performed to investigate the functional role of SIK1-LNC in lung cancer. The results indicated that the cell viabilities of lung cancer cells were enhanced in the overexpression experiment, but attenuated in the knockdown experiment. Additionally, the results also suggested that overexpression of SIK1-LNC remarkably suppressed the proliferative, migrative, and invasive abilities of A549 cells, while knockdown of SIK1-LNC promoted the cell proliferative, migrative, and invasive abilities of H460 cells.

To our knowledge, this may be the first study concerning the expression pattern and functional role of SIK1-LNC in lung cancer. Our data is likely to provide the first evidence regarding the suppressive role of SIK1-LNC in the viability, proliferation, migration, and invasion of lung cancer cells and its association with prognosis of lung cancer. However, the concrete molecular mechanism of SIK1-LNC in lung cancer has not been investigated in this work. Further studies will include the molecular mechanism of SIK1-LNC in lung cancer and its more evidenced potential for a biomarker and therapeutic target for lung cancer on the basis of this paper.

Conclusions
===========

In summary, this study revealed the suppressive role of SIK1-LNC in lung cancer cells. The data provided a new insight into the occurrence and development of lung cancer. Moreover, SIK1-LNC may be a potential therapeutic target in the treatment of lung cancer.
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![Relative SIK1 and SIK1-LNC expressions in 30 lung cancer tissues were examined by RT-qPCR and normalized to GAPDH expression. (**A**) Both SIK1 and (**B**) SIK1-LNC expression were comparatively down-regulated compared to those in matched adjacent normal tissues (*P*\<0.05). (**C**) Correlation analysis between SIK1 and SIK1-LNC expression revealed that SIK1-LNC expression was closely associated with SIK1 expression (N=30, R=0.57, *P*\<0.05).\
**Notes:** Data are presented as fold change in tumor tissues relative to normal tissues. ^\*\*\*^*P*\<0.001, compared with control group.\
**Abbreviations:** SIK1, salt-inducible kinases 1; SIK1-LNC, lincRNA TCONS_00029157.](ott-11-4197Fig1){#f1-ott-11-4197}

![SIK1 expression was co-regulated together with the SIK1-LNC overexpression or knockdown in king cancer cell lines. (**A**) CCK-8 assay indicated A549 cell viability in pcDNA SIK1-LNC groups was lower than that in the pcDNA control group (*P*\<0.05). (**B**) The Brdu assays showed that cell proliferation properties were apparently impaired in the pcDNA SIK1-LNC group when compared with the pcDNA control group (*P*\<0.05). (**C**) The wound healing and (**D**) cell invasion assays indicated that the pcDNA SIK1-LNC group showed significant inhibition on cell migration and invasion, in contrast with the pcDNA control group (*P*\<0.05).\
**Notes:** 200× magnification. \**P*\<0.05, \*\**P*\<0.01, compared with the control group.\
**Abbreviations:** SIKI, salt-inducible kinases 1; SIK1-LNC, lincRNA TCONS_00029157.](ott-11-4197Fig2){#f2-ott-11-4197}

![SIK1-LNC overexpression impaired cell viability, proliferative, migrative, and invasive abilities of A549 cells. (**A**) CCK-8 assay indicated that A549 cell viability in pcDNA SIK1-LNC groups was lower than that in the pcDNA control group (*P*\<0.05). (**B**) The Brdu assays showed that cell proliferation properties were apparently impaired in the pcDNA SIK1-LNC group when compared with the pcDNA control group (*P*\<0.05). (**C**) The wound healing and (**D**) cell invasion assays indicated that the pcDNA SIK1-LNC group showed significant inhibition on cell migration and invasion, in contrast with the pcDNA control group (*P*\<0.05).\
**Notes:** 200× magnification. ^\*^*P*\<0.05, compared with the control group.\
**Abbreviations:** SIKI, salt-inducible kinases 1; SIK1-LNC, lincRNA TCONS_00029157.](ott-11-4197Fig3){#f3-ott-11-4197}

![SIK1-LNC knockdown promoted cell viability, proliferative, migrative, and invasive abilities of H460 cells. (**A**) CCK-8 assays indicated that H460 cell viabilities in SIK1-LNC si-transfected groups were higher than those in the NC si group (*P*\<0.05). (**B**) The Brdu assays suggested that the proliferation of H460 cells was dramatically impaired in SIK1-LNC sil-transfected and SIK1-LNC si2-transfected groups when compared with that in the NC si group (*P*\<0.05). (**C**) The wound healing and (**D**) invasion assays manifested a remarkable increase of cell migration and invasion capacities both in SIK1-LNC sil-transfected and SIK1-LNC si2-transfected groups compared with the NC si group (*P*\<0.05).\
**Notes:** 200× magnification. ^\*^*P*\<0.05, compared with the control group.\
**Abbreviations:** SIK1, salt-inducible kinases 1; SIK1-LNC, lincRNA TCONS \_00029157; SIKl-LNC si, small interfering RNA for SK1-LNC; NC si, negative control siRNA.](ott-11-4197Fig4){#f4-ott-11-4197}

###### 

Correlation between SIK1-LNC expression and clinicopathologic features of lung cancer patients

  Parameters              Group            SIK1-LNC expression   *P*-value   
  ----------------------- ---------------- --------------------- ----------- -------
  Age (years)             \<60             9                     7           0.261
  ≥60                     5                9                                 
  Gender                  Male             7                     6           0.713
  Female                  8                9                                 
  Tumor size (cm)         \<3              6                     6           0.765
  ≥3                      8                10                                
  Histology               Adenoma          11                    5           0.153
  Squamous                6                8                                 
  Differentiation         Moderate--poor   10                    8           0.456
  Well                    5                7                                 
  TNM stage               I + II           10                    7           0.785
  III + IV                7                6                                 
  Lymph node metastasis   Absence          10                    3           0.004
  Presence                4                13                                
  Distant metastasis      Absence          13                    5           0.011
  Presence                3                9                                 

**Abbreviation:** SIK1-LNC, lincRNA TCONS_00029157.

###### 

List of primers used in this study

  Gene                                  Primer sequence (5′ -- 3′)
  ------------------------------------- -----------------------------------
  GAPDH                                 Forward AATGGACAACTGGTCGTGGAC
  Reverse CCCTCCAGGGGATCTGTTTG          
  SIK1                                  Forward CTCCGGGTGGGTTTTTACGAC
  Reverse CTGCGTTTTGGTGACTCGATG         
  SIK1-LNC                              Forward GAATGGGAGGGGAAGGAAGAAGC
  Reverse TCAGCAGAGCAAGAAGAGGTCAG       
  SIK1-LNC si1                          Forward GAAGCUCUUCUUUUGUGGAAUCUGA
  Reverse UCAGAUUCCACAAAAGAAGAGCUUCUU   
  SIK1-LNC si2                          Forward AAGCUCUUCUUUUGUGGAAUCUGAT
  Reverse AUCAGAUUCCACAAAAGAAGAGCUUCU   
  SIK1 si1                              Forward GAACUUUCUGCUUCAUGUAUCAGTT
  Reverse AACUGAUACAUGAAGCAGAAAGUUCAC   
  SIK1 si2                              Forward AACUUUCUGCUUCAUGUAUCAGUTT
  Reverse AAACUGAUACAUGAAGCAGAAAGUUCA   

**Abbreviations:** GAPDH, glyceraldehyde-3-phosphate dehydrogenase; SIK1, salt-inducible kinases 1; SIK1-LNC, lincRNA TCONS_00029157; SIK1-LNC si, small interfering RNA for SIK1-LNC; SIK1 si, small interfering RNA for SIK1.
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